• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OCTREOTIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • OCTREOTIDE chembl:CHEMBL1680 ApprovedAntineoplastic

    Alternate Names:

    SMS-995
    SANDOSTATIN
    SMS 201-995
    SMS995
    SMS-201-995
    OCTREOTIDE

    Drug Info:

    Drug Class hormone replacement agents
    Drug Class antineoplastic agents, hormonal
    Year of Approval 1988
    Drug Indications antihypertensive agent
    FDA Approval approved
    Drug Class peptide
    Drug Indications antineoplastic agent
    (1 More Sources)

    Publications:

    Wang et al., 2005, [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma]., Zhonghua Zhong Liu Za Zhi
    Jaquet et al., 2005, BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide., J. Endocrinol. Invest.
    Ruan et al., 2006, SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?, Mol. Endocrinol.
    Schmid et al., 2005, Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats., J. Endocrinol. Invest.
    Matrone et al., 2004, Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs., Neuroendocrinology
    John et al., 1996, Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2., Gut
    Yim et al., 2009, Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers., Bioconjug. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Plöckinger et al., 2008, Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas., J. Clin. Endocrinol. Metab.
    Shimon, 2003, Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs., Endocrine
    Theodoropoulou et al., 2006, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression., Cancer Res.
    Bronstein, 2006, Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome., Front Horm Res
    Xie et al., 2005, [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2]., Ai Zheng
    Mimuro et al., 1998, The somatostatin analogue, octreotide, modifies both steroidogenesis and IGFBP-1 secretion in human luteinizing granulosa cells., Hum. Reprod.
    Fredstorp et al., 1994, Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide., Clin. Endocrinol. (Oxf)
    Sener et al., 2004, Octreotide ameliorates alendronate-induced gastric injury., Peptides
    Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg
    Cervia et al., 2008, Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas., J. Neurochem.
    Kostoglou-Athanassiou et al., 2003, Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature., Horm. Res.
  • OCTREOTIDE   SSTR1

    Interaction Score: 5.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name CAM-2029
    Novel drug target Established target
    Trial Name oral octreotide actetate ,Octreolin

    PMIDs:
    16438887 16625841 16223973 16625842 15103227 8566856


    Sources:
    TdgClinicalTrial NCI TEND

  • OCTREOTIDE   SSTR5

    Interaction Score: 4.33

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name CAM-2029
    Novel drug target Established target
    Trial Name injectable octreotide acetate,Sandostatin LAR

    PMIDs:
    16438887 16809928 16625841 16625842 16086874


    Sources:
    TdgClinicalTrial TEND

  • OCTREOTIDE   LPAR2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18624922


    Sources:
    NCI

  • OCTREOTIDE   SSTR2

    Interaction Score: 3.61

    Interaction Types & Directionality:
    agonist (activating)
    binder

    Interaction Info:
    Trial Name oral octreotide actetate,Octreolin
    Trial Name octrotide,Atrigel
    Trial Name injectable octreotide acetate,Sandostatin LAR

    PMIDs:
    19537708 11752352 18198230 12721506


    Sources:
    TdgClinicalTrial NCI TTD

  • OCTREOTIDE   IGFBP1

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9512248 7525123


    Sources:
    NCI

  • OCTREOTIDE   TG

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14530610


    Sources:
    NCI

  • OCTREOTIDE   KLK3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7515212


    Sources:
    NCI

  • OCTREOTIDE   MPO

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15003363


    Sources:
    NCI

  • OCTREOTIDE   PIK3CB

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16452215


    Sources:
    NCI

  • OCTREOTIDE   PIK3CG

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16452215


    Sources:
    NCI

  • TEND: OCTREOTIDE

    • Version: 01-August-2011

    Alternate Names:
    OCTREOTIDE Primary Drug Name

    Drug Info:
    Year of Approval 1988
    Drug Class antineoplastic agents, hormonal
    Drug Class hormone replacement agents

    Publications:

  • TdgClinicalTrial: OCTREOTIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class peptide
    FDA Approval approved

    Publications:

  • NCI: OCTREOTIDE

    • Version: 14-September-2017

    Alternate Names:
    C711 NCI drug code

    Drug Info:

    Publications:
    Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg
    Shimon, 2003, Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs., Endocrine
    Plöckinger et al., 2008, Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas., J. Clin. Endocrinol. Metab.

  • TTD: Octreotide

    • Version: 2020.06.01

    Alternate Names:
    D02XIY TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1680

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21